Enclosed herewith Revised Outcome of the Board Meeting held on May 30,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evexia Lifecare filed a revised board meeting outcome for May 30, 2025 after initially omitting the financial attachments. The company reported standalone revenue of ₹8,402 lakhs for FY25, up 51% from ₹5,576 lakhs last year, but standalone net profit fell 37% to ₹73 lakhs. Q4 standalone swung to a loss of ₹49 lakhs versus a ₹273 lakh profit a year earlier. Consolidated revenue jumped 94% to ₹11,063 lakhs but consolidated net profit dropped 32% to ₹93 lakhs. The statutory auditor (M.A. Shah & Co.) issued a qualified opinion on both sets of results, flagging material misstatements, improper valuation of investments, missing documentation, prolonged unrecoverable trade receivables, inadequate liquidity, and substantial tax/regulatory penalties incurred by the company and subsidiaries. Standalone operating cash flow was sharply negative at -₹593 lakhs. The board also appointed Ms. Krupalibahen Rajeshbhai Mehta as an Independent Director for a 5-year term.
Negative for shareholders – the qualified audit opinion with repetitive qualifications signals serious weaknesses in financial reporting and internal controls, while declining profitability despite strong revenue growth and negative operating cash flows raise red flags about earnings quality and liquidity. The stock is likely to face downward pressure given the disclosed audit qualifications and tax/regulatory penalty exposure.